Back to Search
Start Over
High intratumoural galectin-1 expression predicts adverse outcome in ALK− ALCL and CD30+ PTCL-NOS
- Source :
- Holst, J M, Ludvigsen, M, Hamilton-Dutoit, S J, Bendix, K, Plesner, T L, Nørgaard, P, Møller, M B, Steiniche, T, Rabinovich, G A, d'Amore, F & Pedersen, M B 2020, ' High intratumoural galectin-1 expression predicts adverse outcome in ALK − ALCL and CD30 + PTCL-NOS ', Hematological Oncology, vol. 38, no. 1, pp. 59-66 . https://doi.org/10.1002/hon.2702, Holst, J M, Ludvigsen, M, Hamilton-Dutoit, S J, Bendix, K, Plesner, T L, Nørgaard, P, Møller, M B, Steiniche, T, Rabinovich, G A, d'Amore, F & Pedersen, M B 2020, ' High intratumoural galectin-1 expression predicts adverse outcome in ALK-ALCL and CD30+ PTCL-NOS ', Hematological Oncology, vol. 38, no. 1, pp. 59-66 . https://doi.org/10.1002/hon.2702
- Publication Year :
- 2020
-
Abstract
- Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoural Gal-1 expression by immunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumour microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval CI, 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95% CI, 30-64, P =.021). In univariate analyses age 60 or younger, non-elevated lactate dehydrogenase (LDH), and performance score less than 2 correlated with superior survival but high Gal-1 expression significantly predicted adverse outcome at both univariate (HR 2.5, 95% CI, 1.1-5.7, P =.026) and multivariate levels (HR 3.2, 95% CI, 1.2-8.5, P =.017). Tumours with high Gal-1 had few cytotoxic T cells in the tumour microenvironment. High intratumoural Gal-1 expression before therapeutic intervention correlates with adverse outcome in nodal CD30+, ALK− PTCL patients.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
CD30
DIAGNOSIS
DISEASE
MALIGNANCIES
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Lactate dehydrogenase
Internal medicine
PERIPHERAL T-CELL
Galectin-1
LYMPHOMA
medicine
peripheral T-cell lymphoma
GENE-EXPRESSION
CLASSICAL HODGKIN
Univariate analysis
business.industry
STERNBERG CELLS
Hematology
General Medicine
medicine.disease
CANCER
Confidence interval
Peripheral T-cell lymphoma
Lymphoma
chemistry
030220 oncology & carcinogenesis
Cohort
immunohistochemistry
Immunohistochemistry
prognosis
business
030215 immunology
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Holst, J M, Ludvigsen, M, Hamilton-Dutoit, S J, Bendix, K, Plesner, T L, Nørgaard, P, Møller, M B, Steiniche, T, Rabinovich, G A, d'Amore, F & Pedersen, M B 2020, ' High intratumoural galectin-1 expression predicts adverse outcome in ALK − ALCL and CD30 + PTCL-NOS ', Hematological Oncology, vol. 38, no. 1, pp. 59-66 . https://doi.org/10.1002/hon.2702, Holst, J M, Ludvigsen, M, Hamilton-Dutoit, S J, Bendix, K, Plesner, T L, Nørgaard, P, Møller, M B, Steiniche, T, Rabinovich, G A, d'Amore, F & Pedersen, M B 2020, ' High intratumoural galectin-1 expression predicts adverse outcome in ALK-ALCL and CD30+ PTCL-NOS ', Hematological Oncology, vol. 38, no. 1, pp. 59-66 . https://doi.org/10.1002/hon.2702
- Accession number :
- edsair.doi.dedup.....56f5e786286e583d143b666280a9c84a